Asset Details
Do you wish to reserve the book?
Cancer risks of hematopoietic/lymphatic and urinary system in pharmaceutical plant workers: a systematic review and meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cancer risks of hematopoietic/lymphatic and urinary system in pharmaceutical plant workers: a systematic review and meta-analysis
Do you wish to request the book?
Cancer risks of hematopoietic/lymphatic and urinary system in pharmaceutical plant workers: a systematic review and meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cancer risks of hematopoietic/lymphatic and urinary system in pharmaceutical plant workers: a systematic review and meta-analysis
2025
Overview
Introduction
In this study, we will investigate the risk of hematopoietic/lymphatic system and urinary system cancers in pharmaceutical plant workers.
Methods
Six pre-defined inclusion criteria were applied. The quality of all included studies was assessed based on the National Toxicology Program Office of Health Assessment and Translation Risk of Bias tool. Conventional meta-analysis was conducted for hematopoietic/lymphatic system and urinary system cancers. Between-study heterogeneity and publication bias were investigated.
Results
In this systematic review and meta-analysis, four cohort studies of a single pharmaceutical plant, one case-control study, and one cohort study with a nested case-control study were included. For publication bias, the p-value for Egger’s regression test was 0.51 and 0.38 for hematopoietic/lymphatic and urinary system cancer, respectively. Pharmaceutical plant workers showed a 3.19 (95% confidence interval, CI 1.53–6.64) times higher risk of hematopoietic/lymphatic system cancers than the general population. They also showed a 4.86 (95% CI 1.71–13.80) times higher risk of urinary system cancers compared to the general population. Higgins’ I-squared value for between-study heterogeneity was 61.77% (95% CI 0.00–99.06%) and 58.00% (95% CI 0.00–98.67%), respectively.
Conclusion
From this systematic review and meta-analysis, the authors concluded that potential hazardous occupational exposures of workers in pharmaceutical plants could pose an increased risk of hematopoietic/lymphatic system and urinary system cancer. Future studies should be conducted with a more thorough dose-response relationship distinction.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Cancer
/ Hematologic Neoplasms - chemically induced
/ Hematologic Neoplasms - epidemiology
/ Humans
/ Medicine
/ Occupational Diseases - epidemiology
/ Occupational Exposure - adverse effects
/ Pharmaceutical plant workers
/ Urologic Neoplasms - chemically induced
/ Urologic Neoplasms - epidemiology
/ Vaccine
